In our cohort, pathogenic variants in seven established pancreatic cancer‐predisposition genes (ATM, BRCA1, BRCA2, CDKN2A, MSH6, PALB2, and PMS2) were found in 6.4% (95% confidence interval [CI], 4.25–8.55) of case‐patients versus 1.7% (95% CI, 1.60–1.87) of controls (Table S3).37 This evidence concerns the gene PALB2 and familial pancreatic carcinoma.